CEO Michael H. Davidson Sells $14.75M in Company Stock Following Option Exercise
NAMS has more than doubled off its 52-week low of $14.06 on elevated volume (2.4× avg).
Summary
NewAmsterdam Pharma's CEO, Michael H. Davidson, sold $14.75 million worth of company stock after exercising options, a significant transaction that may signal a lack of confidence.
Key Events · Ownership and Investor Activity · NAMS
-
CEO Sells Substantial Stake
Michael H. Davidson, CEO and Director, sold 443,707 ordinary shares for a total of $14,753,257.75 at a price of $33.25 per share.
-
Option Exercise Precedes Sale
The sale followed the exercise of options for an equal number of shares, indicating a planned liquidation of vested equity.
-
Significant Transaction Value
The total value of the shares sold represents 0.777% of the company's current market capitalization, a notable disposition by a top executive.
-
Execution of Prior Intent
This Form 4 filing confirms the actual sale, executing on the intent to sell previously indicated by a Form 144 filed by Davidson on the same date.
Analysis · NAMS · Life Sciences
Michael H. Davidson, Chief Executive Officer and Director of NewAmsterdam Pharma, executed a significant sale of company stock. This transaction involved exercising options and immediately selling the acquired shares, resulting in a net disposition of over $14.75 million. This substantial sale by a key executive, representing 0.777% of the company's market capitalization, could be interpreted negatively by investors, especially given the recent pattern of insider distribution. This Form 4 filing confirms the actual sale, following a Form 144 filed by Davidson on the same day indicating his intent to sell.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.2% of the 386 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAMS was trading at $32.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $14.06 to $42.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.